![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: LRRC31 |
Gene summary for LRRC31 |
![]() |
Gene information | Species | Human | Gene symbol | LRRC31 | Gene ID | 79782 |
Gene name | leucine rich repeat containing 31 | |
Gene Alias | HEL-S-293 | |
Cytomap | 3q26.2 | |
Gene Type | protein-coding | GO ID | NA | UniProtAcc | Q6UY01 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
79782 | LRRC31 | HCC1_Meng | Human | Liver | HCC | 2.37e-21 | 7.73e-02 | 0.0246 |
79782 | LRRC31 | HCC2_Meng | Human | Liver | HCC | 4.93e-06 | 6.66e-02 | 0.0107 |
79782 | LRRC31 | HCC1 | Human | Liver | HCC | 5.10e-04 | 9.23e-01 | 0.5336 |
79782 | LRRC31 | HCC2 | Human | Liver | HCC | 4.15e-09 | 1.95e+00 | 0.5341 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Liver | ![]() | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
LRRC31 | SNV | Missense_Mutation | c.1018N>A | p.Leu340Ile | p.L340I | Q6UY01 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-BS-A0UV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | |
LRRC31 | SNV | Missense_Mutation | rs773962418 | c.1331N>T | p.Ser444Leu | p.S444L | Q6UY01 | protein_coding | tolerated(0.21) | benign(0.011) | TCGA-EO-A3AV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | CR |
LRRC31 | SNV | Missense_Mutation | c.1573N>A | p.Leu525Ile | p.L525I | Q6UY01 | protein_coding | tolerated(0.12) | benign(0.031) | TCGA-EO-A3B0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | |
LRRC31 | SNV | Missense_Mutation | rs747923117 | c.1432N>T | p.Arg478Trp | p.R478W | Q6UY01 | protein_coding | tolerated(0.05) | benign(0) | TCGA-EY-A1G8-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
LRRC31 | SNV | Missense_Mutation | novel | c.597N>T | p.Lys199Asn | p.K199N | Q6UY01 | protein_coding | deleterious(0.05) | possibly_damaging(0.572) | TCGA-EY-A215-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
LRRC31 | insertion | Frame_Shift_Ins | novel | c.102dupA | p.Glu35ArgfsTer4 | p.E35Rfs*4 | Q6UY01 | protein_coding | TCGA-B5-A3FC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
LRRC31 | SNV | Missense_Mutation | c.1601A>G | p.Glu534Gly | p.E534G | Q6UY01 | protein_coding | tolerated(0.11) | benign(0.012) | TCGA-DD-A1EF-01 | Liver | liver hepatocellular carcinoma | Female | <65 | I/II | Unknown | Unknown | PD | |
LRRC31 | SNV | Missense_Mutation | c.1083G>T | p.Arg361Ser | p.R361S | Q6UY01 | protein_coding | tolerated(0.05) | benign(0.42) | TCGA-55-A4DF-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
LRRC31 | SNV | Missense_Mutation | c.279N>C | p.Leu93Phe | p.L93F | Q6UY01 | protein_coding | deleterious(0.02) | probably_damaging(0.996) | TCGA-67-3771-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
LRRC31 | SNV | Missense_Mutation | novel | c.47N>G | p.Pro16Arg | p.P16R | Q6UY01 | protein_coding | tolerated(0.06) | benign(0.07) | TCGA-86-6851-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |